Dx & Vx Co., Ltd. Logo

Dx & Vx Co., Ltd.

A bio-healthcare company specializing in diagnostics and mRNA vaccine development.

180400 | KO

Overview

Corporate Details

ISIN(s):
KR7180400004
LEI:
Country:
South Korea
Address:
서울특별시 금천구 디지털로 173, 금천구

Description

Dx & Vx Co., Ltd. is a bio-healthcare company specializing in diagnostics and vaccine development. Its diagnostics division offers molecular diagnostic solutions, genomics and bioinformatics services, and customized companion diagnostics (CDx), leveraging an AI-based genome analysis platform. The company's therapeutic pipeline is centered on an innovative mRNA vaccine platform designed for long-term storage at room temperature. Key development areas include vaccines for infectious diseases, immuno-therapeutic cancer vaccines, oral treatments for obesity, and therapies for eye conditions. Additionally, Dx & Vx provides contract development, manufacturing, and sales organization (CDMO/CSO) services and commercializes microbiome-based products and health supplements.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-04-23 00:00
단일판매ㆍ공급계약체결
Korean 9.7 KB
2020-04-16 00:00
기타경영사항(자율공시)(상환전환우선주의 보통주 전환청구)
Korean 10.0 KB
2020-04-13 00:00
[기재정정]기타경영사항(자율공시)(상환전환우선주의 보통주 전환청구)
Korean 14.0 KB
2020-04-10 00:00
주주총회소집결의
Korean 7.1 KB
2020-04-10 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.6 KB
2020-04-03 00:00
기타시장안내(감사의견 관련 형식적 상장폐지 사유해소 및 매매거래정지 지속 안내)
Korean 4.2 KB
2020-04-03 00:00
주권매매거래정지기간변경(상장폐지 사유 해소)
Korean 4.7 KB
2020-04-01 00:00
기타경영사항(자율공시)(상환전환우선주의 보통주 전환청구)
Korean 10.6 KB
2020-03-31 00:00
[기재정정]사업보고서 (2018.12)
Korean 680.3 KB
2020-03-31 00:00
[기재정정]사업보고서 (2018.12)
Korean 642.7 KB
2020-03-30 00:00
정기주주총회결과
Korean 18.7 KB
2020-03-30 00:00
기타시장안내(개선계획 이행내역서 제출에 따른 안내)
Korean 3.8 KB
2020-03-26 00:00
기타경영사항(자율공시)(사업보고서 등 지연제출에 대한 제재 면제 심사 결과(승인))
Korean 5.0 KB
2020-03-23 00:00
[기재정정]감사보고서제출(2018사업연도)
Korean 44.5 KB
2020-03-23 00:00
[기재정정]감사보고서제출(2017사업연도)
Korean 26.4 KB

Automate Your Workflow. Get a real-time feed of all Dx & Vx Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dx & Vx Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dx & Vx Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.